Correction to: Dermatology: Endocannabinoids and Related N-Acylethanolamines in the Skin

Vincenzo Miragliotta and Chiara Noli

Correction to:
Chapter 9 in: S. Cital et al. (eds.), *Cannabis Therapy*
***in Veterinary Medicine*,**
https://doi.org/10.1007/978-3-030-68317-7_9

Owing to an oversight on the part of the editor, the original version of Chapter 9 was inadvertently published with the below text. The text has been removed and the chapter has now been corrected and approved by the authors.

“Awaiting publication, a randomized, double-blinded, placebo controlled clinical study led by Dr. Margaret Curtis in Australia, found in 13 dogs the use of a multi-phytocannabinoid product (DermaCann[®]) substantially reduced Canine Atopic Dermatitis Extent and Severity Index (CADESI-4) scores by an average of 51% after 56 days on treatment. Plasma skin inflammatory biomarkers, Chemokine Ligand 1 (CXCL1) and Chemokine Ligand 2 (CCL2), we also markedly reduced. No significant adverse events were reported for this study. (Personal communication with Layton Mills, Managing Director at CannPal, 7/19/20)”

The updated online version of this chapter can be found at
https://doi.org/10.1007/978-3-030-68317-7_9